Company / R&D per Share
Merck & Co. R&D per Share History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest R&D per Share
$6.20
FY2025
5-year range
$4.75 / $12.03
FY2021-FY2025
Trend
-12.2%
vs FY2024
Sector context
#24 of 208
Health Care
What the data says
Merck & Co.'s r&d per share of $6.20 is higher than 88% of companies in the Health Care sector (FY2025). R&D per Share has fluctuated over the past 10 years, ranging from $3.50 in FY2018 to $12.03 in FY2023.
Based on SEC 10-K filings.
6.20 in FY2025 with a 5-year CAGR of +4.4%. Top quartile in the Health Care sector.
Declined from $12.03 to $6.20 over the past 2 years.
Health Care sector context is included.
R&D per Share over time
Growth rates
- 3-Year CAGR
- +5.2%
- 5-Year CAGR
- +4.4%
- 10-Year CAGR
- -
Sector benchmark
Top 12% in Health CareTop 12% of 208This company $6.20 Sector average $28.82
▼
-78.5% below sector average
Key checks
Key Insights
- In FY2025, r&d per share decreased 12.2% year-over-year.
- Ranks #24 out of 208 companies in the Health Care sector.
- Peak r&d per share was recorded in FY2023.
- Lowest r&d per share in the period was in FY2018.
Company context
Key Data Points
- Strong profit margin: 29.6%
- Strong return on equity: 36.7%
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | R&D per ShareValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $6.20 | -12.2% |
| FY2024 | $7.06 | -41.3% |
| FY2023 | $12.03 | +125.6% |
| FY2022 | $5.33 | +12.3% |
| FY2021 | $4.75 | -5.1% |
| FY2020 | $5.00 | +41.3% |
| FY2019 | $3.54 | +1.1% |
| FY2018 | $3.50 | -3.8% |
| FY2017 | $3.64 | +3.8% |
| FY2016 | $3.50 | +56.6% |
As of FY2025 · SEC 10-K · Updated Mar 9, 2026